Randomized, Double-blind, Placebo-controlled, Dose Exploration, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
Latest Information Update: 25 Apr 2025
At a glance
- Drugs Salbutamol sulfate (Primary) ; TQC 3721 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 17 Apr 2025 Status changed from recruiting to completed.
- 17 Aug 2023 New trial record